Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

AVITA Medical Advises on US FDA Approving the Expanded Use of the RECELL System

11 Jun 2021  |  08:47:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: U.S. FDA Approves Expanded Use of the RECELL System

AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is indicated to treat full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age). In addition, the indication includes treatment for full-thickness thermal burns that extend beyond 50% total body surface area (TBSA).

Please click here for full details

See more ASX300 News Announcements